Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PMM2 | O15305 | 1/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30230909 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL11234930 | 0.82 | INPPL1 (0.40) | SMN1; SMN2TSHRCYP3A4GPR35POLB | |
| SCHEMBL113455 | 0.80 | MAPK1 (0.44) | TSHRGPR35POLBMAPK1ALDH1A1 | |
| SCHEMBL29445407 | 0.80 | MAPK1 (0.44) | TSHRGPR35POLBMAPK1ALDH1A1 | |
| SCHEMBL761929 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL985995 | 0.78 | AHR (0.51) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL29780392 | 0.78 | AHR (0.51) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL12161594 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL1507262 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL131620 | 0.77 | GPR35 (0.57) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115109048-A | (hetero) aryl amide compound | 中国药科大学 | 2022-09-27 | — | — | CN | claimed |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20240425504-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (assignee) (JP) | 2024-12-26 | — | — | US | disclosed |
| EP-3808747-B1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL (JP) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024199444-A1 | HETEROAROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翊维康医药有限责任公司 | 2024-10-03 | — | — | WO | disclosed |
| US-12077531-B2 | Imidazopyridinone compound | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-08-29 | — | — | US | disclosed |
| US-4824951-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-04-25 | — | — | US | disclosed |
| US-4772600-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC | A. H. ROBINS COMPANY, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0255217-A1 | Fused imidazoheterocyclic compounds | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-02-03 | — | — | EP | disclosed |
| US-4698430-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INC. (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0068834-B1 | PYRIMIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-09-03 | — | — | EP | disclosed |
| US-4558132-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| US-4535163-A | ANTIHISTAMINES; PYRIMIDONE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-08-13 | — | — | US | disclosed |
| US-4444772-A | 2-(3,5-DISUBSTITUTED-PYRIDYLALKYLAMINO)-5-PYRIDYLMETHYL-4 -PYRIMIDONE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-04-24 | — | — | US | disclosed |
| EP-0099614-A2 | Nitro, amino and aroylamino-N-phenylpyridinamines and their use in a process for preparing pyrido(1,4)benzodiazapines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-02-01 | — | — | EP | disclosed |
| EP-0068834-A2 | Pyrimidinone derivatives and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077531-B2 | Imidazopyridinone compound | EGLN3, DHPS, EGLN2 | SMN1; SMN2 3895/4885TSHR 4705/4885CYP3A4 1438/4885 |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | SMN1; SMN2 1175/4885TSHR 773/4885CYP3A4 27/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | SMN1; SMN2 3101/4885TSHR 2680/4885CYP3A4 134/4885 |
| US-20240425504-A1 | IMIDAZOPYRIDINONE COMPOUND | EGLN3, DHPS, EGLN2 | SMN1; SMN2 3895/4885TSHR 4705/4885CYP3A4 1438/4885 |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP11B2, CYP4X1 | SMN1; SMN2 1434/4885TSHR 1665/4885CYP3A4 10/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | SMN1; SMN2 1434/4885TSHR 1665/4885CYP3A4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.